A Phase 3 interventional study of Herpes Zoster vaccine GSK 1437173A and GSK Biologicals' quadrivalent seasonal influenza vaccine FLU-D-QIV GSK2321138A in Herpes Zoster, sponsored by GlaxoSmithKline. Completed at 20 sites in 3 countries. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-05-02.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies testing shingrix in Herpes Zoster — 8 open to participants now, 11 under way, 3 of them phase 3. shingrix · Herpes Zoster.
Among the 46 studies testing shingrix in Herpes Zoster, this one is the 13th largest by enrollment, is one of 4 that started in 2013, is one of 22 in phase 3, and was the 11th registered.
299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.
Browse Herpes Zoster studies →8 of the 46 studies testing shingrix in Herpes Zoster are open now, in 5 countries. Recruiting first, the newest first:
GlaxoSmithKline · Sites in Finland
Ages 76+ · Healthy volunteers
Seoul National University Hospital · Sites in Korea, Republic of
Ages 19+
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18+ · Healthy volunteers
Loyola University · Sites in United States
University of Colorado, Denver · Sites in United States
Ages 18–70
By country, each count listing its studies:
shingrix: first FDA approval 2017 (Shingrix). What it is approved for, and how studies give it, is on its page →
Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.
This study: 50 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 10 · Phase 3 22 · Phase 4 8
First in 2009; this study’s year is marked. 4 started in 2013.
This study's enrollment of 829 is above the median of 160 across 247 interventional studies indexed under Herpes Zoster.
Median enrollment 239 across the 46 interventional studies. Of the 32 that completed or were terminated, 27 (84%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 46 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
44 studies in Herpes Zoster by GlaxoSmithKline: 3 open now, 5 under way, 1 of them phase 3. Of 39 finished, 34 (87%) have results posted.
Among the 44 studies in Herpes Zoster by GlaxoSmithKline, this one is the 14th largest by enrollment of the 37 interventional ones that give a count, is one of 8 that started in 2013, is one of 25 in phase 3, and was the 21st registered.
GlaxoSmithKline’s Herpes Zoster studies by the year they started, since 2007.
4 of the studies testing shingrix in Herpes Zoster that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05371080Phase 3GlaxoSmithKlineA Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults | 2027-08-23 |
| NCT05580458National Institute of Allergy and Infectious Diseases (NIAID)Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population | 2027-02-01 |
| NCT06162494Ann & Robert H Lurie Children's Hospital of ChicagoRecombinant Zoster Vaccine in Young Adult Solid Organ Transplant Recipients | 2027-03-31 |
| NCT06569823Dynavax Technologies CorporationSafety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and Over | 2027-06 |
Add all 4 to your calendar (.ics) → With an account.
Among the 46 studies testing shingrix in Herpes Zoster, from their registry updates:
Among GlaxoSmithKline’s 44 in Herpes Zoster:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess immunogenicity, reactogenicity and safety of GSK Biologicals' HZ/su vaccine when its first dose is co-administered with the FLU-D-QIV vaccine in adults aged 50 years or older compared to administration of vaccines separately.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Female subjects of non- may be enrolled in the study.
Female subjects of childbearing potential may be enrolled in the study, if the subject:
Exclusion Criteria:
Acute disease and/or fever at the time of enrolment.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The subjects assigned to the Co-Ad group will receive one injection of the FLU-D-QIV vaccine and one injection of the HZ/su study vaccine during the first visit and a second injection of the HZ/su study vaccine during the third visit, two months later.
Biological: Herpes Zoster vaccine GSK 1437173A · Biological: GSK Biologicals' quadrivalent seasonal influenza vaccine FLU-D-QIV GSK2321138A
The subjects assigned to the Control group will receive all vaccines separately: one injection of the FLU-D-QIV vaccine at the first visit, one injection of the HZ/su study vaccine at the third visit and a second injection of the HZ/su study vaccine at the fourth visit, all two months apart.
Biological: Herpes Zoster vaccine GSK 1437173A · Biological: GSK Biologicals' quadrivalent seasonal influenza vaccine FLU-D-QIV GSK2321138A
2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
2 doses administered intramuscularly (IM) in the deltoid region of the dominant arm.
Also known as: Influsplit™ Tetra (Germany), Fluarix™ Quadrivalent (United States)
Number of Subjects With Vaccine Response to Anti-gE Antibodies
The vaccine response(VRR) for anti-gE humoral immunogenicity, as determined by enzyme-linked immunosorbent assay (ELISA),was assessed only in subjects from the GSK1437173A + GSK2321138A Group. The VRR for anti-gE was defined as the percentage of subjects who had at least: a 4-fold increase in the post-dose 2 anti-gE antibody concentration as compared to the pre-vaccination anti-gE antibody concentration, for subjects who were seropositive at baseline (cut-off ≥ 97 mIU/ml), or, a 4-fold increase in the post dose 2 anti-gE antibody concentrations as compared to the anti-gE antibodies cut-off value for seropositivity, for subjects who were seronegative at baseline (cut-off \< 97 mIU/ml).
Time frame: At one month post-dose 2 (Month 3)
Vaccine Response for Anti-gE Humoral Immunogenicity
The vaccine response(VRR) for anti-gE humoral immunogenicity, as determined by enzyme-linked immunosorbent assay (ELISA),was assessed only in subjects from the GSK1437173A + GSK2321138A Group. The VRR for anti-gE was defined as the percentage of subjects who had at least: a 4-fold increase in the post-dose 2 anti-gE antibody concentration as compared to the pre-vaccination anti-gE antibody concentration, for subjects who were seropositive at baseline (cut-off ≥ 97 mIU/ml), or, a 4-fold increase in the post dose 2 anti-gE antibody concentrations as compared to the anti-gE antibodies cut-off value for seropositivity, for subjects who were seronegative at baseline (cut-off \< 97 mIU/ml).Criterion used: the objective was met if the Lower Limit (LL) of the 95% confidence interval (CI) of the VRR for anti-gE antibody concentrations was at least 60%.
Time frame: At one month post-dose 2 (Month 3)
Adjusted Geometric Mean ELISA Concentrations of Anti-gE Antibodies
Geometric means (GMs) of post-vaccination concentrations (Month 3 for GSK1437173A + GSK2321138A group and Month 5 for Control group) was calculated conditionally to the means of the pre-vaccination log-transformed concentrations for anti-gE (Month 0 for GSK1437173A + GSK2321138A group and Month 2 for Control group). Adjusted Least Squares (LS) means and difference of LS means between the groups were calculated together with 2-sided 95% CIs and back-transformed to the original units to provide GMCs.
Time frame: At one month post-dose 2 (Month 3 for GSK1437173A + GSK2321138A group and Month 5 for Control group)
FLU Haemagglutination Inhibition (HI) Antibody Titers
For each strain included in the FLU-D-QIV vaccine, an ANOVA model was used to analyze post-vaccination log-transformed titers. The fixed-effect model included the minimization variable (age cohorts) and the treatment as fixed effect. The pre-vaccination log-transformed concentrations were included as continuous covariate. Geometric Means (GM) of post-vaccination titers (Day 21) were calculated conditionally to the means of the pre-vaccination log-transformed titers (Month 0) for each strain. Adjusted GMTs (GMTs adjusted for baseline titers) and Adjusted GMT ratios were calculated together with 2-sided 95% CIs.
Time frame: At Day 21 post vaccination
Number of Subjects With FLU HI Antibody Titers ≥1:10
FLU HI antibodies were assessed in four strains: Flu A/California/7/2009 H1N1, Flu A/Texas/50/2012 H3N2, Flu B/Brisbane/60/2008 Victoria and Flu B/Massachusetts (Massach)/2/2012 Yamagata (Yama). Cut-off titer for seropositivity was 1:10.
Time frame: At Day 0 (PRE) and 21 post vaccination
Number of Seroprotected Subjects With HI Antibody Titers ≥ 1:40
Seroprotection rate is defined as the percentage of vaccines with a serum HI titer ≥1:40 that usually was accepted as indicating protection. FLU HI antibodies were assessed in four strains: Flu A/California/7/2009 H1N1, Flu A/Texas/50/2012 H3N2, Flu B/Brisbane/60/2008 Victoria (Vic) and Flu B/Massachusetts(Massach)/2/2012 Yamagata (Yama).
Time frame: At Day 0 (PRE) and at Day 21 post vaccination
FLU Haemagglutination Inhibition (HI) Antibody Titers
HI antibody titres against the four influenza vaccine strains Flu A/California/7/2009, Flu A/Texas/50/2012, Flu B/Brisbane/60/2008 Victoria (Vic) and Flu B/Massachusetts (Massach)/2/2012 Yamagata (Yamma) were expressed as geometric mean titers (GMTs).
Time frame: At Day 0 (PRE) and Day 21 post vaccination
Number of Seroconverted Subjects in Terms of HI Antibodies
The number of seroconverted subjects was assessed in terms of HI antibodies against the four influenza vaccine strains Flu A/California/7/2009, Flu A/Texas/50/2012, Flu B/Brisbane/60/2008 Victoria and Flu B/Massachusetts/2/2012 Yamagata.
Time frame: At Day 21 post vaccination
Geometric Mean Ratio for Flu HI Antibodies Post-vaccination Titer
The geometric mean ratio for Flu HI antibodies against the four influenza vaccine strains Flu A/California/7/2009, Flu A/Texas/50/2012, Flu B/Brisbane/60/2008 Victoria and Flu B/Massachusetts/2/2012 Yamagata was defined as the geometric mean of the within subject ratios of the post-vaccination reciprocal HI titer to the Day 0 reciprocal HI titer.
Time frame: At Day 21 post vaccination
Number of Subjects With Solicited Local Symptoms
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 (G3) pain = pain that prevented normal activity. Grade 3 (G3) redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site. Relationship analysis was not performed.
Time frame: Within 7 days (Days 0-6) after each vaccine dose
Number of Subjects With Solicited Local Symptoms
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site. Relationship analysis was not performed.
Time frame: Within 7 days (Days 0-6) across doses
Number of Subjects With Solicited General Symptoms
Assessed solicited general symptoms were arthralgia, fatigue, gastrointestinal symptoms, headache, myalgia, shivering and fever \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.
Time frame: Within 7 days (Days 0-6) after each vaccine dose
Number of Subjects With Solicited General Symptoms
Assessed solicited general symptoms were arthralgia, fatigue, gastrointestinal symptoms, headache, myalgia, shivering and fever \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.
Time frame: Within 7 days (Days 0-6) across doses
Number of Subjects With Unsolicited Adverse Events (AEs)
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.
Time frame: During 30 days (Days 0-29) after vaccination
Number of Subjects With Serious Adverse Events (SAEs)
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Time frame: From first vaccination up to Month 18 (study end)
Number of Subjects With Potential Immune-mediated Diseases (pIMDs)
pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.
Time frame: From first vaccination up to Month 18 (study end)
| Milestone | GSK1437173A + GSK2321138A Group | Control Group |
|---|---|---|
| Started | 413 | 415 |
| Completed | 400 | 396 |
| Not completed | 13 | 19 |
| Withdrew: Adverse event | 5 | 7 |
| Withdrew: Lost to follow-up | 6 | 6 |
| Withdrew: Withdrawal by subject | 2 | 6 |
The vaccine response(VRR) for anti-gE humoral immunogenicity, as determined by enzyme-linked immunosorbent assay (ELISA),was assessed only in subjects from the GSK1437173A + GSK2321138A Group. The VRR for anti-gE was defined as the percentage of subjects who had at least: a 4-fold increase in the post-dose 2 anti-gE antibody concentration as compared to the pre-vaccination anti-gE antibody concentration, for subjects who were seropositive at baseline (cut-off ≥ 97 mIU/ml), or, a 4-fold increase in the post dose 2 anti-gE antibody concentrations as compared to the anti-gE antibodies cut-off value for seropositivity, for subjects who were seronegative at baseline (cut-off \< 97 mIU/ml).
| Subjects | GSK1437173A + GSK2321138A Group |
|---|---|
| Number of Subjects With Vaccine Response to Anti-gE Antibodies | 366 |
The vaccine response(VRR) for anti-gE humoral immunogenicity, as determined by enzyme-linked immunosorbent assay (ELISA),was assessed only in subjects from the GSK1437173A + GSK2321138A Group. The VRR for anti-gE was defined as the percentage of subjects who had at least: a 4-fold increase in the post-dose 2 anti-gE antibody concentration as compared to the pre-vaccination anti-gE antibody concentration, for subjects who were seropositive at baseline (cut-off ≥ 97 mIU/ml), or, a 4-fold increase in the post dose 2 anti-gE antibody concentrations as compared to the anti-gE antibodies cut-off value for seropositivity, for subjects who were seronegative at baseline (cut-off \< 97 mIU/ml).Criterion used: the objective was met if the Lower Limit (LL) of the 95% confidence interval (CI) of the VRR for anti-gE antibody concentrations was at least 60%.
| Percentage | GSK1437173A + GSK2321138A Group |
|---|---|
| Vaccine Response for Anti-gE Humoral Immunogenicity | 95.8 (93.3 to 97.6) |
Geometric means (GMs) of post-vaccination concentrations (Month 3 for GSK1437173A + GSK2321138A group and Month 5 for Control group) was calculated conditionally to the means of the pre-vaccination log-transformed concentrations for anti-gE (Month 0 for GSK1437173A + GSK2321138A group and Month 2 for Control group). Adjusted Least Squares (LS) means and difference of LS means between the groups were calculated together with 2-sided 95% CIs and back-transformed to the original units to provide GMCs.
| mIU/mL | GSK1437173A + GSK2321138A Group | Control Group |
|---|---|---|
| Adjusted Geometric Mean ELISA Concentrations of Anti-gE Antibodies | 52151.6 (48356.0 to 56245.2) | 56247.4 (52177.3 to 60634.9) |
For each strain included in the FLU-D-QIV vaccine, an ANOVA model was used to analyze post-vaccination log-transformed titers. The fixed-effect model included the minimization variable (age cohorts) and the treatment as fixed effect. The pre-vaccination log-transformed concentrations were included as continuous covariate. Geometric Means (GM) of post-vaccination titers (Day 21) were calculated conditionally to the means of the pre-vaccination log-transformed titers (Month 0) for each strain. Adjusted GMTs (GMTs adjusted for baseline titers) and Adjusted GMT ratios were calculated together with 2-sided 95% CIs.
| Titers | GSK1437173A + GSK2321138A Group | Control Group |
|---|---|---|
| Flu A/California/7/2009 H1N1 HI Day 21 | 187.5 (166.7 to 210.8) | 194.3 (173.0 to 218.1) |
| Flu A/Texas/50/2012 H3N2 HI Day 21 | 63.7 (58.3 to 69.7) | 65.9 (60.3 to 72.0) |
| Flu B/Brisbane/60/2008 Victoria HI Day 21 | 170.2 (156.1 to 185.6) | 181.6 (166.7 to 197.8) |
| Flu B/Massachusetts/2/2012 Yamagata HI Day 21 | 423.5 (392.0 to 457.5) | 413.9 (383.4 to 446.8) |
FLU HI antibodies were assessed in four strains: Flu A/California/7/2009 H1N1, Flu A/Texas/50/2012 H3N2, Flu B/Brisbane/60/2008 Victoria and Flu B/Massachusetts (Massach)/2/2012 Yamagata (Yama). Cut-off titer for seropositivity was 1:10.
| Subjects | GSK1437173A + GSK2321138A Group | Control Group |
|---|---|---|
| Flu A/California/7/2009 H1N1 Day 0 [N=386,395] | 288 | 294 |
| Flu A/California/7/2009 H1N1Day 21 [N=384,394] | 381 | 389 |
| Flu A/Texas/50/2012 H3N2 Day 0 [N=386,395] | 283 | 300 |
| Flu A/Texas/50/2012 H3N2 Day 21 [N=384,394] | 380 | 392 |
| Flu B/Brisbane/60/2008 Victoria Day 0 [N=386,395] | 365 | 375 |
| Flu B/Brisbane/60/2008 Victoria Day 21 [N=384,394] | 383 | 394 |
| Flu B/Massach/2/2012 Yama Day 0 [N=386,395] | 376 | 389 |
| Flu B/Massach/2/2012 Yama Day21 [N=384,394] | 384 | 394 |
Seroprotection rate is defined as the percentage of vaccines with a serum HI titer ≥1:40 that usually was accepted as indicating protection. FLU HI antibodies were assessed in four strains: Flu A/California/7/2009 H1N1, Flu A/Texas/50/2012 H3N2, Flu B/Brisbane/60/2008 Victoria (Vic) and Flu B/Massachusetts(Massach)/2/2012 Yamagata (Yama).
| Subjects | GSK1437173A + GSK2321138A Group | Control Group |
|---|---|---|
| Flu A/California/7/2009 H1N1 HI Day 0 [N=386,395] | 185 | 161 |
| Flu A/California/7/2009 H1N1 HI Day 21 [N=384,394] | 347 | 360 |
| Flu A/Texas/50/2012 H3N2 HI Day 0 [N=386,395] | 134 | 121 |
| Flu A/Texas/50/2012 H3N2 HI Day 21 [N=384,394] | 292 | 295 |
| Flu B/Brisbane/60/2008 Vic HI Day 0 [N=386,395] | 279 | 271 |
| Flu B/Brisbane/60/2008 Vic HI Day 21 [N=384,394] | 372 | 382 |
| Flu B/Massach/2/2012 Yama HI Day 0 [N=386,395] | 351 | 361 |
| Flu B/Massach/2/2012 Yama HI Day 21 [N=384,394] | 383 | 393 |
HI antibody titres against the four influenza vaccine strains Flu A/California/7/2009, Flu A/Texas/50/2012, Flu B/Brisbane/60/2008 Victoria (Vic) and Flu B/Massachusetts (Massach)/2/2012 Yamagata (Yamma) were expressed as geometric mean titers (GMTs).
| Titers | GSK1437173A + GSK2321138A Group | Control Group |
|---|---|---|
| Flu A/California/7/2009 H1N1 HI Day 0 [N=386,395] | 29 (25.1 to 33.5) | 24.9 (21.8 to 28.5) |
| Flu A/California/7/2009 H1N1 HI Day 21[N=384,394] | 196.2 (172.2 to 223.5) | 193.2 (170.2 to 219.4) |
| Flu A/Texas/50/2012 H3N2 HI Day 0 [N=386,395] | 19.6 (17.5 to 21.9) | 19.0 (17.1 to 21.1) |
| Flu A/Texas/50/2012 H3N2 HI Day 21 [N=384,394] | 65.4 (59.0 to 72.5) | 66.8 (60.4 to 74.0) |
| Flu B/Brisbane/60/2008 Vic HI Day 0 [N=386,395] | 52.2 (46.9 to 58.1) | 48.6 (43.7 to 54) |
| Flu B/Brisbane/60/2008 Vic HI Day 21 [N=384,394] | 177.2 (161.6 to 194.2) | 185.2 (168 to 204.1) |
| Flu B/Massach/2/2012 Yama HI Day 0 [N=386,395] | 128.8 (115.7 to 143.4) | 127 (114.9 to 140.3) |
| Flu B/Massach/2/2012 Yama HI Day 21 [N=384,394] | 433.7 (401.3 to 468.7) | 423.3 (388 to 461.8) |
The number of seroconverted subjects was assessed in terms of HI antibodies against the four influenza vaccine strains Flu A/California/7/2009, Flu A/Texas/50/2012, Flu B/Brisbane/60/2008 Victoria and Flu B/Massachusetts/2/2012 Yamagata.
| Subjects | GSK1437173A + GSK2321138A Group | Control Group |
|---|---|---|
| Flu A/California/7/2009 H1N1 HI | 232 | 240 |
| Flu A/Texas/50/2012 H3N2 HI | 136 | 139 |
| Flu B/Brisbane/60/2008 Victoria HI | 143 | 169 |
| Flu B/Massachusetts/2/2012 Yamagata HI | 154 | 148 |
The geometric mean ratio for Flu HI antibodies against the four influenza vaccine strains Flu A/California/7/2009, Flu A/Texas/50/2012, Flu B/Brisbane/60/2008 Victoria and Flu B/Massachusetts/2/2012 Yamagata was defined as the geometric mean of the within subject ratios of the post-vaccination reciprocal HI titer to the Day 0 reciprocal HI titer.
| Ratio | GSK1437173A + GSK2321138A Group | Control Group |
|---|---|---|
| Flu A/California/7/2009 H1N1 HI | 6.8 (5.9 to 7.8) | 7.7 (6.7 to 9) |
| Flu A/Texas/50/2012 H3N2 HI | 3.4 (3.0 to 3.7) | 3.5 (3.2 to 4.0) |
| Flu B/Brisbane/60/2008 Victoria HI | 3.4 (3 to 3.8) | 3.8 (3.4 to 4.3) |
| Flu B/Massachusetts/2/2012 Yamagata HI | 3.4 (3 to 3.7) | 3.3 (3 to 3.7) |
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 (G3) pain = pain that prevented normal activity. Grade 3 (G3) redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site. Relationship analysis was not performed.
| Subjects | GSK1437173A + GSK2321138A Group | Control Group |
|---|---|---|
| Any Pain D1 GSK 2321138A [N=410;412] | 140 | 112 |
| G3 Pain D1 GSK 2321138A [N=410;412] | 7 | 4 |
| Any Redness D1 GSK 2321138A [N=410;412] | 31 | 37 |
| G3 Redness D1 GSK 2321138A [N=410;412] | 1 | 2 |
| Any Swelling D1 GSK 2321138A [N=410;412] | 16 | 18 |
| G3 Swelling D1 GSK 2321138A [N=410;412] | 0 | 1 |
| Any Pain D2 GSK 2321138A [N=0;0] | NA | NA |
| G3 Pain D2 GSK 2321138A [N=0;0] | NA | NA |
| Any Redness D2 GSK 2321138A [N=0;0] | NA | NA |
| G3 Redness D2 GSK 2321138A [N=0;0] | NA | NA |
| Any Swelling D2 GSK 2321138A [N=0;0] | NA | NA |
| G3 Swelling D2 GSK 2321138A [N=0;0] | NA | NA |
| Any Pain D1 GSK 1437173A [N=410;0] | 292 | NA |
| G3 Pain D1 GSK 1437173A [N=410;0] | 31 | NA |
| Any Redness D1 GSK 1437173A [N=410;0] | 112 | NA |
| G3 Redness D1 GSK 1437173A [N=410;0] | 4 | NA |
| Any Swelling D1 GSK 1437173A [N=410;0] | 64 | NA |
| G3 Swelling D1 GSK 1437173A [N=410;0] | 0 | NA |
| Any Pain D2 GSK 1437173A [N=403;405] | 290 | 280 |
| G3 Pain D2 GSK 1437173A [N=403;405] | 32 | 25 |
| Any Redness D2 GSK 1437173A [N=403;405] | 103 | 91 |
| G3 Redness D2 GSK 1437173A [N=403;405] | 5 | 6 |
| Any Swelling D2 GSK 1437173A [N=403;405] | 64 | 47 |
| G3 Swelling D2 GSK 1437173A [N=403;405] | 0 | 0 |
| Any Pain D3 GSK 2321138A [N=0;0] | NA | NA |
| G3 Pain D3 GSK 2321138A [N=0;0] | NA | NA |
| Any Redness D3 GSK 2321138A [N=0;0] | NA | NA |
| G3 Redness D3 GSK 2321138A [N=0;0] | NA | NA |
| Any Swelling D3 GSK 2321138A [N=0;0] | NA | NA |
| G3 Swelling D3 GSK 2321138A [N=0;0] | NA | NA |
| Any Pain D3 GSK 1437173A [N=0;402] | NA | 269 |
| G3 Pain D3 GSK 1437173A [N=0;402] | NA | 25 |
| Any Redness D3 GSK 1437173A [N=0;402] | NA | 100 |
| G3 Redness D3 GSK 1437173A [N=0;402] | NA | 7 |
| Any Swelling D3 GSK 1437173A [N=0;402] | NA | 50 |
| G3 Swelling D2 GSK 1437173A [N=0;402] | NA | 4 |
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site. Relationship analysis was not performed.
| Subjects | GSK1437173A + GSK2321138A Group | Control Group |
|---|---|---|
| Any Pain Across Doses | 344 | 318 |
| Grade 3 Pain Across Doses | 55 | 40 |
| Any Redness Across Doses | 153 | 144 |
| Grade 3 Redness Across Doses | 9 | 14 |
| Any Swelling Across Doses | 99 | 86 |
| Grade 3 Swelling Across Doses | 0 | 5 |
Assessed solicited general symptoms were arthralgia, fatigue, gastrointestinal symptoms, headache, myalgia, shivering and fever \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.
| Subjects | GSK1437173A + GSK2321138A Group |
|---|---|
| Any Arthralgia Dose 1 [N=409] | 89 |
| Grade 3 Arthralgia Dose 1 [N=409] | 8 |
| Related Arthralgia Dose 1 [N=409] | 67 |
| Any Fatigue Dose 1 [N=409] | 150 |
| Grade 3 Fatigue Dose 1 [N=409] | 15 |
| Related Fatigue Dose 1 [N=409] | 107 |
| Any Gastrointestinal Dose 1 [N=409] | 57 |
| Grade 3 Gastrointestinal Dose 1 [N=409] | 5 |
| Related Gastrointestinal Dose 1 [N=409] | 28 |
| Any Headache Dose 1 [N=409] | 122 |
| Grade 3 Headache Dose 1 [N=409] | 5 |
| Related Headache Dose 1 [N=409] | 80 |
| Any Myalgia Dose 1 [N=409] | 135 |
| Grade 3 Myalgia Dose 1 [N=409] | 11 |
| Related Myalgia Dose 1 [N=409] | 105 |
| Any Shivering Dose 1 [N=409] | 101 |
| Grade 3 Shivering Dose 1 [N=409] | 12 |
| Related Shivering Dose 1 [N=409] | 86 |
| Any Temperature Dose 1 [N=409] | 63 |
| Grade 3 Temperature Dose 1 [N=409] | 1 |
| Related Temperature Dose 1 [N=409] | 53 |
| Any Arthralgia Dose 2 [N=402] | 114 |
| Grade 3 Arthralgia Dose 2 [N=402] | 16 |
| Related Arthralgia Dose 2 [N=402] | 94 |
| Any Fatigue Dose 2 [N=402] | 167 |
| Grade 3 Fatigue Dose 2 [N=402] | 23 |
| Related Fatigue Dose 2 [N=402] | 138 |
| Any Gastrointestinal Dose 2 [N=402] | 47 |
| Grade 3 Gastrointestinal Dose 2 [N=402] | 3 |
| Related Gastrointestinal Dose 2 [N=402] | 32 |
| Any Headache Dose 2 [N=402] | 136 |
| Grade 3 Headache Dose 2 [N=402] | 16 |
| Related Headache Dose 2 [N=402] | 109 |
| Any Myalgia Dose 2 [N=402] | 157 |
| Grade 3 Myalgia Dose 2 [N=402] | 18 |
| Related Myalgia Dose 2 [N=402] | 135 |
| Any Shivering Dose 2 [N=402] | 142 |
| Grade 3 Shivering Dose 2 [N=402] | 30 |
| Related Shivering Dose 2 [N=402] | 122 |
| Any Temperature Dose 2 [N=402] | 74 |
| Grade 3 Temperature Dose 2 [N=402] | 1 |
| Related Temperature Dose 2 [N=402] | 63 |
Assessed solicited general symptoms were arthralgia, fatigue, gastrointestinal symptoms, headache, myalgia, shivering and fever \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.
| Subjects | Control Group |
|---|---|
| Any Arthralgia, Dose 1 [N=411] | 37 |
| Grade 3 Arthralgia, Dose 1 [N=411] | 8 |
| Related Arthralgia, Dose 1 [N=411] | 25 |
| Any Fatigue, Dose 1 [N=411] | 52 |
| Grade 3 Fatigue, Dose 1 [N=411] | 4 |
| Related Fatigue, Dose 1 [N=411] | 33 |
| Any Gastrointestinal, Dose 1 [N=411] | 32 |
| Grade 3 Gastrointestinal, Dose 1 [N=411] | 2 |
| Related Gastrointestinal, Dose 1 [N=411] | 16 |
| Any Headache, Dose 1 [N=411] | 57 |
| Grade 3 Headache, Dose 1 [N=411] | 2 |
| Related Headache, Dose 1 [N=411] | 31 |
| Any Myalgia, Dose 1 [N=411] | 55 |
| Grade 3 Myalgia, Dose 1 [N=411] | 4 |
| Related Myalgia, Dose 1 [N=411] | 45 |
| Any Shivering, Dose 1 [N=411] | 30 |
| Grade 3 Shivering, Dose 1 [N=411] | 0 |
| Related Shivering, Dose 1 [N=411] | 25 |
| Any Temperature, Dose 1 [N=411] | 18 |
| Grade 3 Temperature, Dose 1 [N=411] | 0 |
| Related Temperature, Dose 1 [N=411] | 15 |
| Any Arthralgia, Dose 2 [N=405] | 67 |
| Grade 3 Arthralgia, Dose 2 [N=405] | 6 |
| Related Arthralgia, Dose 2 [N=405] | 51 |
| Any Fatigue, Dose 2 [N=405] | 108 |
| Grade 3 Fatigue, Dose 2 [N=405] | 9 |
| Related Fatigue, Dose 2 [N=405] | 87 |
| Any Gastrointestinal, Dose 2 [N=405] | 37 |
| Grade 3 Gastrointestinal, Dose 2 [N=405] | 1 |
| Related Gastrointestinal, Dose 2 [N=405] | 28 |
| Any Headache, Dose 2 [N=405] | 87 |
| Grade 3 Headache, Dose 2 [N=405] | 8 |
| Related Headache, Dose 2 [N=405] | 70 |
| Any Myalgia, Dose 2 [N=405] | 135 |
| Grade 3 Myalgia, Dose 2 [N=405] | 7 |
| Related Myalgia, Dose 2 [N=405] | 115 |
| Any Shivering, Dose 2 [N=405] | 87 |
| Grade 3 Shivering, Dose 2 [N=405] | 10 |
| Related Shivering, Dose 2 [N=405] | 75 |
| Any Temperature, Dose 2 [N=405] | 44 |
| Grade 3 Temperature, Dose 2 [N=405] | 1 |
| Related Temperature, Dose 2 [N=405] | 34 |
| Any Arthralgia, Dose 3 [N=402] | 95 |
| Grade 3 Arthralgia, Dose 3 [N=402] | 18 |
| Related Arthralgia, Dose 3 [N=402] | 79 |
| Any Fatigue, Dose 3 [N=402] | 149 |
| Grade 3 Fatigue, Dose 3 [N=402] | 31 |
| Related Fatigue, Dose 3 [N=402] | 120 |
| Any Gastrointestinal, Dose 3 [N=402] | 63 |
| Grade 3 Gastrointestinal, Dose 3 [N=402] | 6 |
| Related Gastrointestinal, Dose 3 [N=402] | 46 |
| Any Headache, Dose 3 [N=402] | 133 |
| Grade 3 Headache, Dose 3 [N=402] | 23 |
| Related Headache, Dose 3 [N=402] | 111 |
| Any Myalgia, Dose 3 [N=402] | 138 |
| Grade 3 Myalgia, Dose 3 [N=402] | 24 |
| Related Myalgia, Dose 3 [N=402] | 121 |
| Any Shivering, Dose 3 [N=402] | 147 |
| Grade 3 Shivering, Dose 3 [N=402] | 23 |
| Related Shivering, Dose 3 [N=402] | 131 |
| Any Temperature, Dose 3 [N=402] | 87 |
| Grade 3 Temperature, Dose 3 [N=402] | 2 |
| Related Temperature, Dose 3 [N=402] | 70 |
Assessed solicited general symptoms were arthralgia, fatigue, gastrointestinal symptoms, headache, myalgia, shivering and fever \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.
| Subjects | GSK1437173A + GSK2321138A Group | Control Group |
|---|---|---|
| Any Arthralgia, Across Doses | 154 | 135 |
| Grade 3 Arthralgia, Across Doses | 23 | 24 |
| Related Arthralgia, Across Doses | 121 | 110 |
| Any Fatigue, Across Doses | 224 | 186 |
| Grade 3 Fatigue, Across Doses | 30 | 38 |
| Related Fatigue, Across Doses | 175 | 151 |
| Any Gastrointestinal, Across Doses | 90 | 92 |
| Grade 3 Gastrointestinal, Across Doses | 6 | 9 |
| Related Gastrointestinal, Across Doses | 49 | 66 |
| Any Headache, Across Doses | 183 | 170 |
| Grade 3 Headache, Across Doses | 20 | 28 |
| Related Headache, Across Doses | 140 | 142 |
| Any Myalgia, Across Doses | 201 | 201 |
| Grade 3 Myalgia, Across Doses | 27 | 30 |
| Related Myalgia, Across Doses | 167 | 177 |
| Any Shivering, Across Doses | 174 | 181 |
| Grade 3 Shivering, Across Doses | 35 | 30 |
| Related Shivering, Across Doses | 151 | 159 |
| Any Temperature, Across Doses | 107 | 119 |
| Grade 3 Temperature, Across Doses | 2 | 3 |
| Related Temperature, Across Doses | 90 | 96 |
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.
| Subjects | GSK1437173A + GSK2321138A Group | Control Group |
|---|---|---|
| Any AEs | 110 | 162 |
| Grade 3 AEs | 17 | 29 |
| Related AEs | 18 | 26 |
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
| Subjects | GSK1437173A + GSK2321138A Group | Control Group |
|---|---|---|
| Number of Subjects With Serious Adverse Events (SAEs) | 42 | 39 |
pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.
| Subjects | GSK1437173A + GSK2321138A Group | Control Group |
|---|---|---|
| Number of Subjects With Potential Immune-mediated Diseases (pIMDs) | 4 | 2 |
Collected over Systematically-assessed symptoms: Days 0-7 post each vaccine dose; AEs: Days 0-29 post each vaccine dose; SAEs: from Day 0 to Month 18. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GSK1437173A + GSK2321138A Group | — | 42/413 (10.2%) | 370/413 (89.6%) |
| Control Group | — | 39/415 (9.4%) | 369/415 (88.9%) |
| Event | GSK1437173A + GSK2321138A Group | Control Group |
|---|---|---|
| Coronary artery diseaseCardiac disorders | 3/413 | 1/415 |
| Cerebrovascular accidentNervous system disorders | 3/413 | 0/415 |
| PneumoniaInfections and infestations | 3/413 | 0/415 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 1/413 | 3/415 |
| SyncopeNervous system disorders | 2/413 | 1/415 |
| Angina unstableCardiac disorders | 2/413 | 0/415 |
| UrosepsisInfections and infestations | 2/413 | 0/415 |
| Atrial fibrillationCardiac disorders | 1/413 | 2/415 |
| HypertensionVascular disorders | 1/413 | 2/415 |
| PancreatitisGastrointestinal disorders | 0/413 | 2/415 |
| Event | GSK1437173A + GSK2321138A Group | Control Group |
|---|---|---|
| PainGeneral disorders | 344/411 | 318/413 |
| FatigueGeneral disorders | 224/411 | 186/413 |
| MyalgiaGeneral disorders | 201/411 | 201/413 |
| HeadacheGeneral disorders | 183/411 | 170/413 |
| ShiveringGeneral disorders | 174/411 | 181/413 |
| ArthralgiaGeneral disorders | 154/411 | 135/413 |
| RednessGeneral disorders | 153/411 | 144/413 |
| Temperature/(Oral)General disorders | 107/411 | 119/413 |
| SwellingGeneral disorders | 99/411 | 86/413 |
| GastrointestinalGeneral disorders | 90/411 | 92/413 |
| Age, Continuous(Years) | GSK1437173A + GSK2321138A Group | Control Group | Total |
|---|---|---|---|
| Mean | 63.4 ± 8.3 | 63.4 ± 8.8 | 63.4 ± 8.55 |
| Sex: Female, Male(Participants) | GSK1437173A + GSK2321138A Group | Control Group | Total |
|---|---|---|---|
| Female | 211 | 218 | 429 |
| Male | 202 | 197 | 399 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
The record gives a start of Oct 2013, a primary completion of Jun 2014 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2016, 1 year 8 months after primary completion. A results delay was requested in Jun 2015.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Shingrix